GT Biopharma (GTBP) investor relations material

Platform overview and scientific progress

• Advancing immuno-oncology therapies using the proprietary TriKE platform to enhance the immune system's ability to target cancer cells, focusing on both blood cancers and solid tumors.

• TriKE molecules are engineered to engage natural killer (NK) cells, providing targeted activation and minimizing side effects compared to traditional chemotherapy.

• The second-generation camelid TriKE, now in phase I trials, shows improved tumor control and safety, with ongoing enrollment in both blood cancer and solid tumor studies.

• TriKE's modular design allows for rapid adaptation to different targets, including CD33 for AML/MDS, B7-H3 for solid tumors, and CD19 for autoimmune diseases.

• Early clinical data indicate dose-dependent NK cell activation, expansion, and initial signs of anti-tumor activity with minimal adverse effects.

Clinical development and trial updates

• Two phase I trials are ongoing: one for blood cancers (GTB-3650) and one basket trial for solid tumors (GTB-5550), targeting multiple cancer types.

• The solid tumor trial includes prostate, breast, bladder, pancreatic, head and neck, and lung cancers, with B7-H3 as a pan-tumor target expressed in over 80% of these cancers.

• GTB-5550 is administered subcutaneously in an outpatient setting, aiming for patient-friendly dosing and potential self-administration in the future.

• Early safety data show only mild, transient fevers, and the trials are designed to escalate doses and extend treatment cycles to assess durability of response.

• Efficacy data from the current phase I cohorts are expected soon, with key milestones anticipated by year-end and early next year.

Commercial and strategic positioning

• The TriKE platform's adaptability and cost-effectiveness position it favorably against cell therapies like CAR-T, with per-patient trial costs significantly lower.

• High-value transactions in the NK cell engager space highlight strong commercial potential if clinical success is achieved.

• The platform approach is attractive to potential partners, as it enables expansion into multiple indications, including autoimmune diseases and infectious diseases like HIV.

• Leadership team combines deep scientific expertise with commercial and financial experience, supporting both innovation and execution.